Back to search results

Observational Study of HPV DNA/RNA for Cervical Cancer Treatment Response

This study is looking at new ways to track how well cervical cancer treatment is working. Researchers are testing two commercially available technologies, NavDx and Quantivirus HPV (Human Papillomavirus) DNA, to see if they can accurately detect HPV-related DNA and RNA in your blood. This could help doctors understand if surgery, radiation, or chemotherapy has been effective. You might be able to join if you are a woman aged 18 to 89, have HPV-associated cervical cancer (squamous cell, adenocarcinoma, or adenosquamous), and have evaluable disease. The goal is to see if these blood tests can show how your cancer is responding to treatment. The study is currently observational, meaning it will watch and collect information, but the status of recruitment is unclear.

Study design
This is an observational study involving 55 participants. It will compare two commercially available tests, NavDx and Quantivirus HPV DNA, side-by-side.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your treatment response will be evaluated from enrollment until your first surveillance visit, which is 3-4 months after surgery or chemotherapy, or at your 3-4 month follow-up radiation therapy visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07214584

Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy

Recruiting
Not specifiedAges 18–89Observational
University of Florida
~55 participants
Updated 2026-02-12 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of Circulating HPV DNA/mRNA Liquid Biopsy for Evaluating Treatment Response in Cervical Cancer
Measured over From enrollment to the end of the first surveillance visit, which occurs at 3-4 months post op or post-chemo, or at the patient's 3-4 month follow-up radiation therapy visit.

Conditions

Cervical Cancer
Human Papilloma Virus (HPV)

Explore related trials

Cervical CarcinomaHPV

Where it's being run

1 sites across 1 states
Florida1

Who to contact

Kari S Bastow, BS
[email protected]
352-265-8827
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years and older
HPV-associated squamous cell, adenocarcinoma, or adenosquamous cancers of the uterine cervix with evaluable disease
Diagnosed with American Joint Committee on Cancer (AJCC) stage I or higher, or metastatic disease.
Presence of evaluable disease on pre-treatment standard of care imaging with plans to obtain serial post-treatment standard of care imaging
Agree to perform the required research-related blood tests and cervical mucous testing.
Unable to comply with follow up scheduling.
Diagnosed with a synchronous malignancy requiring cancer-directed therapy

Exclusion

Unable to consent or refusal to sign a consent form

What this trial measures

  • Feasibility of Circulating HPV DNA/mRNA Liquid Biopsy for Evaluating Treatment Response in Cervical CancerFrom enrollment to the end of the first surveillance visit, which occurs at 3-4 months post op or post-chemo, or at the patient's 3-4 month follow-up radiation therapy visit.

    This is a feasibility study to determine the sensitivity of circulating HPV DNA/mRNA, measured by either or both NavDx or Quantivirus as a liquid biopsy, to evaluate treatment response in cervical cancer.